The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | An overview of the immunotherapy landscape in AML: antibodies, bispecifics, & CAR-T
Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, provides an overview of the current landscape of immunotherapy in acute myeloid leukemia (AML), discussing antibody-drug conjugates, monoclonal antibodies, bispecifics, and CAR T-cell therapy. Dr Subklewe highlights results from past and ongoing clinical trials and comments on future directions in this area. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
